Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc’s previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc.

预计在纳斯达克上市将为Tevogen Bio Holdings Inc.提供更多资金，以加速为大量患者群体开发其未经基因修饰的现成T细胞治疗产品。新泽西州沃伦，2024年2月14日（环球通讯社）--Tevogen Bio Holdings Inc.（“Tevogen Bio”），一家临床阶段专业免疫治疗生物技术先驱，在病毒学、肿瘤学和神经病学领域开发现成的、未经基因修饰的T细胞疗法，宣布完成Tevogen Bio Inc.先前宣布的与Semper Paratus Acquisition Corporation的业务合并，导致Tevogen Bio Holdings Inc.的成立。

The combined company’s common stock and warrants will begin trading on Nasdaq Global Market (“Nasdaq”) under the ticker symbols TVGN and TVGNW, respectively, beginning Thursday, February 15, 2024. The listing with Nasdaq is expected to provide Tevogen Bio increased access to capital to accelerate the development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.

合并后的公司的普通股和认股权证将于2024年2月15日（星期四）开始在纳斯达克全球市场（Nasdaq）上分别以股票代码TVGN和TVGNW进行交易。在纳斯达克上市有望为Tevogen Bio提供更多的资金来源，以加速其针对大量患者群体的未经基因修饰的现成T细胞治疗产品的开发。

This innovative platform leverages one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, with the aim of addressing the significant unmet needs of large patient populations.

这个创新平台利用自然界最强大的免疫武器之一CD8+细胞毒性T淋巴细胞，开发现成的精确T细胞疗法，用于治疗传染病，癌症和神经系统疾病，旨在解决大量患者群体的重大未满足需求。

ExacTcell stands in contrast with both autologous and allogeneic CAR-T platforms, which target antigens present on both healthy and diseased cells and require genetic modification of the T cells. Dr. Ryan Saadi, Chief Executive Officer and Chairperson of Tevogen Bio Inc, and the current management team, including Kirti Desai, Chief Financial Officer, Dr.

ExacTcell与自体和同种异体CAR-T平台形成对比，后者靶向健康和患病细胞上存在的抗原，需要对T细胞进行基因修饰。Tevogen Bio Inc首席执行官兼主席Ryan Saadi博士，以及目前的管理团队，包括首席财务官Kirti Desai博士。

Neal Flomenberg, Chief Scie.

Neal Flomenberg，首席Scie。